What can we expect in 2023
Members of our Editorial Advisory Board discuss their expectations for triglyceride-related research in 2023 and its potential impact for patients at increased risk of cardiovascular (CV) disease and pancreatitis.
Chris Packard, Professor of Vascular Biochemistry at the University of Glasgow, UK, looks forward to fresh insights into the contrasting results of the REDUCE-IT and PROMINENT trials and the impact of changes in triglyceride rich lipoproteins on atherosclerosis.Watch the video
Derick Raal, Head of Lipidology and Endocrinology at Johannesburg Hospital, South Africa, anticipates research to further understand possible targets for ANGPTL3 and apoCIII inhibition, and outcome studies to establish their effects on cardiovascular events.Watch the video
Rob Hegele, Jacob J Wolfe Distinguished Medical Research Chair, Robarts Research Institute, Ontario, Canada, hopes that patient genotyping in hypertriglyceridaemia trials will help predict response to novel therapies, and cardiovascular benefits.Watch the video
Anne Goldberg, Professor of Medicine, Washington University School of Medicine, USA, is eager to find out if targeting apoCIII with antisense oligonucleotide or mRNA silencing approaches may lead the way to novel treatments for severe chylomicronaemia.Watch the video
For a round-up of key points from the videos, Read the commentary here »
Fourth Closed Scientific Expert Meeting of the Editorial Board
Dr Philip Gordts explains that, in pre-clinical models, apoCIII ASO treatment has been shown mainly to improve plaque stability, and triglyceride lowering is needed in order to achieve cardiovascular disease benefits.
Professor Sander Kersten reviews the evidence showing that pharmacological strategies to inactivate ANGPTL3 result in lowering of plasma TG and LDL-C, and reports recent data related to ANGPTL3, 4, and 8 activity and inhibition.Watch presentation
Professor Daniel Gaudet explains that mechanisms of ANGPTL3/8 dual blockade are different from ANGPTL3 inhibition alone, and the impact of ANGPTL3/8 inhibition on endothelial lipase-dependent remnant clearance and HDL metabolism is unclear.Watch presentation
New APOC3 loss-of-function data support apoCIII as a treatment target for CV disease prevention
Professor Marja-Riitta Taskinen reviews new APOC3 loss-of-function research aimed at gaining a better understanding of the regulatory role of apoCIII and its potential in atherosclerotic cardiovascular disease prevention.Read the commentary
Cholesterol crystals: The next target for intervention in atherosclerotic cardiovascular disease?
Professor John Chapman discusses the role for cholesterol crystals in atherothrombosis and evidence that ethyl eicosapentaenoic acid may modify crystal formation and deposition, with implications for therapeutic intervention in ASCVD.Read the commentary
Third Closed Scientific Expert Meeting of the Editorial Board
Keynote: What have we learned from triglyceride lowering trials using fibrates over the past 40 years?
Professor Marja-Riitta Taskinen reviews the evidence from the FIELD and ACCORD clinical trials in type 2 diabetes and considers how treatment might be tailored to patients most likely to benefit.
Novel PPAR agonists as therapeutics in hypertriglyceridaemia
Professor Bart Staels discusses latest understanding of the mechanisms of action of PPAR agonists, together with pre-clinical and clinical data on the selective PPARα modulator, pemafibrate.
Triglyceride-rich lipoproteins and their remnants: Commentary on the 2021 EAS Consensus Statement
Professor Gary Lewis (University of Toronto, Canada) discusses the evidence presented in the 2021 EAS Consensus Statement and its implications for clinicians and patients.
ASCVD risk with persistent hypertriglyceridaemia: What is the latest guidance from ACC?
Dr Michael Miller (University of Maryland, Baltimore, USA) discusses the background to the latest ACC guidance and the recommendation to stratify patients for treatment according to their residual LDL-cholesterol level.
Clinical trials of innovative therapeutics
New insights into the biology of triglyceride metabolism underpin the development of novel therapies for managing hypertriglyceridaemia to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) and, for severely elevated levels, pancreatitis.
In the last decade epidemiology and genetic studies – in particular, Mendelian randomisation studies – have moved the field forward and we are on the cusp of a new era in managing elevated triglycerides.
Major outcomes studies with these new therapies are fundamental to answering the much-debated question: Does lowering elevated triglycerides reduce residual cardiovascular risk?
About Triglyceride Forum
The Triglyceride Forum is a unique, independent, expert-led global initiative to address the rapidly evolving field of triglycerides and triglyceride-rich lipoproteins in cardiovascular disease and pancreatitis. This Forum will provide clinicians and researchers with international, open access, peer-reviewed resources at an important time when new and innovative molecules are at advanced stages of development… Read more >>
Professors Ginsberg and Chapman explain the fundamental scientific and clinical research that has turned the spotlight on triglyceride-rich lipoproteins and their remnants as important players in the development of atherosclerotic CVD and pancreatitis and as targets for novel therapies for both these serious diseases.
Join the Triglyceride Forum for open access to independent, evidence based knowledge and high quality educational programmes
View invitation from Henry Ginsberg
Join the Triglyceride Forum to share new data and exchange opinions with clinicians and researchers around the world
View invitation from John Chapman
Meet our Steering Committee
MAKING THE CONNECTION: TRIGLYCERIDES, RESIDUAL CV RISK AND PANCREATITIS
This unique, downloadable slide deck developed specially for Triglyceride Forum is a state-of-the-art guide to triglycerides and their association with residual cardiovascular risk and pancreatitis.